The biotech put the message out in a direct-to-consumer TV ad that paints Vyvgart Hytrulo as a drug that can help people with chronic inflammatory demyelinating polyneuropathy (CIDP) live life to ...
Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a progressive or relapsing neuropathy likely caused by an autoimmune attack on the peripheral nerves. A number of treatment ...
He noted the significant early impact on CIDP and progress in clinical milestones, including advancing empasiprubart and efgartigimod into Phase III programs. Van Hauwermeiren announced that 2025 ...
Dublin, March 05, 2025 (GLOBE NEWSWIRE) -- The "Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Pipeline Insight, 2025" report has been added to ResearchAndMarkets.com's offering.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback